Skip to main content

ALNY Alnylam Pharmaceuticals, Inc.

Healthcare

165.00 Close 10/30
Since 2024-12-02 -34.8%
Open
172.70
High
180.61
Low
163.30
Prev close
174.00
Volume
6.9M
Amplitude
9.95%
P/E
8.3
P/B
6.1
Revenue YoY (TTM)
+56.2%
52W 163.30 479.79

Is Alnylam Pharmaceuticals, Inc. a buy? Fundamentals and valuation first

As of 2026-10-30

Quality: Good, Growth: Strong, Risk / liquidity: Good; Valuation: Pricey, Momentum: Weak.

Valuation Pricey TTM P/E is Cheap, but Price / book is Expensive.
TTM P/E 8.33 20th percentile Cheap
Price / book 6.13 86th percentile Expensive
Free-cash-flow yield (%) 2.27 55th percentile Good
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Good ROE, TTM is Top; FCF margin, TTM is Good.
ROE, TTM (%) 75.59 94th percentile Top
Operating margin, TTM (%) 19.5 71th percentile Good
FCF margin, TTM (%) 9.99 61th percentile Good
Quality Factor Investing: A US Quality Value Backtest
Growth Strong All 2 indicators are Top.
Revenue growth, TTM YoY (%) 56.17 88th percentile Top
Diluted EPS growth, TTM YoY (%) 8,150 99th percentile Top
Momentum Weak 60-day return is Average; 240-day return is Lagging.
60-day return (%) -23.65 23th percentile Average
240-day return (%) -63.26 12th percentile Lagging
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Good 20-day dollar volume is Top, but 60-day annualized volatility is Average.
20-day dollar volume 434,413,398 97th percentile Top
60-day annualized volatility (%) 67.01 69th percentile Average
Factor Investing Explained: 10 Classic Factors in US Stocks

Alnylam Pharmaceuticals, Inc. (ALNY) today

1 quant signals active · As of 2026-10-30

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

FinLab Studio

From Alnylam Pharmaceuticals, Inc. to every stock like it

AI finds several complementary traits of Alnylam Pharmaceuticals, Inc. across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. (ALNY) peers and tracking

Watchlist

This page refreshes daily after the close. Add Alnylam Pharmaceuticals, Inc. to your watchlist to track signal changes on your next visit.

Alnylam Pharmaceuticals, Inc. (ALNY) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

EPS surprise beat

Active · now 879.52%

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

PEAD: Post-Earnings Announcement Drift Backtest
23 historical occurrences (since 2015-02-12)

Average forward return after EPS surprise beat

20-day: Win 38.1%, Sample 21, Median -2.43%, Excess -1.67%, Beat mkt rate 28.6%

60-day: Win 57.1%, Sample 21, Median +1.67%, Excess -0.13%, Beat mkt rate 33.3%

120-day: Win 47.6%, Sample 21, Median -3.97%, Excess +4.69%, Beat mkt rate 33.3%

120 days after: historical avg +12.81%

20-day +0.14%
60-day +5.08%
120-day +12.81%
20-day
60-day
120-day
Win
38.1%
57.1%
47.6%
Sample
21
21
21
Median
-2.43%
+1.67%
-3.97%
Excess
-1.67%
-0.13%
+4.69%
Beat mkt rate
28.6%
33.3%
33.3%

Over 21 occurrences, 120-day forward avg gained 12.81%, beat the market by 4.69 pts; win rate 47.6%.

More history: Market-wide momentum baseline, Signals not active now

Market-wide momentum baseline

Across 99,493 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.42%, a 58.4% positive-return rate, and +3.08 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

21 times historically; 60-day forward avg +4.01%, win rate 52.4%, beating the market by +0.51 pts on average.

Top-quintile 6-month momentum

Pending

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

Momentum Trading Strategy: A 12-1 Momentum Backtest

12 times historically; 60-day forward avg +16.64%, win rate 66.7%, beating the market by +12.79 pts on average.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

14 times historically; 60-day forward avg -1.41%, win rate 50%, beating the market by -4.01 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.